Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?
The search for innovative therapeutic agents in non-small cell lung cancer (NSCLC) has witnessed a swift evolution. The number of targeted drugs that can improve patient outcomes with an acceptable safety profile is steadily increasing. In this review, we highlight current drugs that have already be...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2013-07-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/1758834013492001 |
| id |
doaj-41d425840671486f99c4c99097860c91 |
|---|---|
| record_format |
Article |
| spelling |
doaj-41d425840671486f99c4c99097860c912020-11-25T03:27:54ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83401758-83592013-07-01510.1177/1758834013492001Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?Fadi S. FarhatWissam HouhouThe search for innovative therapeutic agents in non-small cell lung cancer (NSCLC) has witnessed a swift evolution. The number of targeted drugs that can improve patient outcomes with an acceptable safety profile is steadily increasing. In this review, we highlight current drugs that have already been approved or are under evaluation for the treatment of patients with NSCLC, either in monotherapy or combined therapy for both the first- and second-line settings. Experience with drugs targeting the vascular endothelial growth factor and its receptor, as well as the epidermal growth factor receptor is summarized. Moreover, we provide an overview of more novel targets in NSCLC and initial experience with the respective therapeutic agents.https://doi.org/10.1177/1758834013492001 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Fadi S. Farhat Wissam Houhou |
| spellingShingle |
Fadi S. Farhat Wissam Houhou Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? Therapeutic Advances in Medical Oncology |
| author_facet |
Fadi S. Farhat Wissam Houhou |
| author_sort |
Fadi S. Farhat |
| title |
Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? |
| title_short |
Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? |
| title_full |
Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? |
| title_fullStr |
Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? |
| title_full_unstemmed |
Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? |
| title_sort |
targeted therapies in non-small cell lung carcinoma: what have we achieved so far? |
| publisher |
SAGE Publishing |
| series |
Therapeutic Advances in Medical Oncology |
| issn |
1758-8340 1758-8359 |
| publishDate |
2013-07-01 |
| description |
The search for innovative therapeutic agents in non-small cell lung cancer (NSCLC) has witnessed a swift evolution. The number of targeted drugs that can improve patient outcomes with an acceptable safety profile is steadily increasing. In this review, we highlight current drugs that have already been approved or are under evaluation for the treatment of patients with NSCLC, either in monotherapy or combined therapy for both the first- and second-line settings. Experience with drugs targeting the vascular endothelial growth factor and its receptor, as well as the epidermal growth factor receptor is summarized. Moreover, we provide an overview of more novel targets in NSCLC and initial experience with the respective therapeutic agents. |
| url |
https://doi.org/10.1177/1758834013492001 |
| work_keys_str_mv |
AT fadisfarhat targetedtherapiesinnonsmallcelllungcarcinomawhathaveweachievedsofar AT wissamhouhou targetedtherapiesinnonsmallcelllungcarcinomawhathaveweachievedsofar |
| _version_ |
1724586526557339648 |